Litigation Details for VIIV Healthcare Company v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2017)

« Back to Dashboard

VIIV Healthcare Company v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2017)

Docket		Date Filed	2017-11-17
Court	District Court, N.D. West Virginia	Date Terminated	2020-09-04
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	9,242,986
Link to Docket	External link to docket

Details for VIIV Healthcare Company v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-17				External link to document
2017-11-16	174	Memorandum & Opinion	regarding claims 1-6 of U.S. Patent No. 9,242,986 (“the ’986 Patent”) (Dkt. No. 152). After receiving…claims of infringement as to claims 1-6 of the ’986 Patent, and (2) extend ViiV’s deadline to serve its final…the single PXRD peak ignores elementary patent law, which requires more than single-peak analysis…1562, 1566 (Fed. Cir. 1997) (“It is elementary patent law that all limitations are material. The single-peak…2017 4 September 2020 1:17-cv-00197 Patent District Court, N.D. West Virginia	External link to document
2017-11-17	181	Certificate of Service	Craig Echardt, Ph.D. on Invalidity of U.S. Patent No. 9,242,986 B2 and accompanying documents)Dr. Ulus Atasoy… 4 September 2020 1:17-cv-00197 830 Patent None District Court, N.D. West Virginia	External link to document
2017-11-17	188	Certificate of Service	Eckhardt, Ph.D., on the Invalidity of U.S. Patent No. 9,242,986 B2). (O'Brien, William) (Entered: 05/04/… 4 September 2020 1:17-cv-00197 830 Patent None District Court, N.D. West Virginia	External link to document

ViiV Healthcare v. Mylan Pharmaceuticals, Inc. Litigation Summary and Patent Analysis

Last updated: October 21, 2026

ViiV Healthcare Company sued Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware after Mylan filed an abbreviated new drug application seeking approval for generic dolutegravir tablets, the active ingredient in Tivicay. The case, No. 1:17-cv-00197, involved ViiV’s core dolutegravir compound patent and a related method-of-use patent. The dispute was resolved through a settlement rather than a reported merits judgment.

The litigation delayed Mylan’s commercial entry and preserved ViiV’s control over generic dolutegravir access until the negotiated license date. Because dolutegravir is a small-molecule product, biosimilar law does not apply. The relevant FDA pathway was an ANDA with Paragraph IV certifications.

What drug and FDA pathway were at issue in ViiV v. Mylan?

The case concerned generic dolutegravir tablets, an HIV-1 integrase strand transfer inhibitor product marketed by ViiV as Tivicay.

Item	Information
Reference product	Tivicay
Active ingredient	Dolutegravir sodium
Dosage form	Oral tablets
Therapeutic area	HIV-1 infection
NDA holder	ViiV Healthcare Company
FDA pathway for Mylan	ANDA
Certification	Paragraph IV
Case number	1:17-cv-00197
Court	U.S. District Court for the District of Delaware
Filed	February 2017
Patent dispute	Dolutegravir compound and HIV-treatment method claims

The FDA approved Tivicay in 2013 for use with other antiretroviral agents in the treatment of HIV-1 infection. Dolutegravir was also incorporated into combination products, including Triumeq and Juluca, but the Mylan case focused on the dolutegravir tablet product covered by Mylan’s ANDA. (U.S. Food and Drug Administration [FDA], 2013)

What patents did ViiV assert against Mylan?

ViiV asserted patents covering dolutegravir and its use in treating HIV infection. The principal patents associated with the action were U.S. Patent Nos. 8,129,385 and 8,754,065.

Patent	General subject matter	Strategic role
U.S. Patent No. 8,129,385	Carbamoyl pyridone compounds, including dolutegravir	Core compound and composition protection
U.S. Patent No. 8,754,065	Use of dolutegravir for treating HIV infection	Method-of-use protection

The ’385 patent was the principal composition patent. Its claims reached the dolutegravir chemical structure and pharmaceutical compositions containing it. The ’065 patent provided a separate infringement theory based on the use of dolutegravir in HIV treatment.

This two-layer strategy increased ViiV’s leverage. A generic applicant could challenge the compound patent, the method patent, or both. A successful invalidity or non-infringement argument against one patent would not necessarily eliminate the other patent from the case.

How strong was the ViiV patent estate?

ViiV’s estate was commercially strong because it combined:

1. A foundational small-molecule patent directed to dolutegravir.
2. A method-of-use patent directed to the approved HIV indication.
3. FDA-listed patent protection associated with the reference product.
4. Commercial importance across multiple HIV products and fixed-dose combinations.

The compound patent carried the greatest practical value. A valid and enforceable compound patent can block substantially all ordinary generic formulations of the active ingredient. Formulation changes generally do not avoid infringement if the generic product still contains the patented compound or falls within a composition claim.

The method patent was narrower. ANDA applicants can attempt to address method-of-use patents through labeling modifications, including a “section viii” carve-out for protected indications. That option is less useful when the patented method corresponds closely to the product’s principal approved use.

What were Mylan’s Paragraph IV allegations?

Mylan’s ANDA included Paragraph IV certifications asserting that the relevant ViiV patents were invalid, unenforceable, or would not be infringed by the proposed generic product. ViiV’s complaint triggered the statutory 30-month stay of FDA approval under the Hatch-Waxman Act, subject to earlier termination or court action. (21 U.S.C. § 355(j)(5)(B)(iii))

The public case record identifies the dispute as a standard ANDA patent action. The central legal issues were expected to include:

• Whether Mylan’s generic dolutegravir product would infringe the asserted claims.
• Whether the claimed dolutegravir subject matter was valid over prior art.
• Whether the asserted claims satisfied written-description and enablement requirements.
• Whether the method-of-use claims were properly listed and enforceable.
• Whether any labeling carve-out could avoid infringement of the method claims.

There was no reported Delaware trial judgment establishing that Mylan’s product infringed or that the asserted patents were invalid. The case ended through settlement.

When did the ViiV-Mylan case end?

The litigation was resolved by settlement and the case was terminated rather than decided after a reported trial. The settlement allowed Mylan to obtain a license for generic dolutegravir commercialization on a negotiated future date.

The publicly available docket does not provide the complete commercial terms of the agreement. The settlement appears to have preserved ViiV’s effective exclusivity for the period preceding the agreed generic entry date while avoiding the cost and risk of a full patent trial.

Litigation event	Result
ViiV complaint	Filed in February 2017
Mylan response	Paragraph IV ANDA patent challenge
30-month stay	Triggered by the patent suit, subject to statutory rules
Trial outcome	No reported merits judgment
Resolution	Settlement
Case disposition	Terminated following settlement
Generic entry mechanism	Licensed entry under negotiated terms

Did the settlement establish an early generic launch date?

The settlement established a licensed pathway for Mylan, but the complete agreement was not publicly disclosed in the judicial docket. Public reporting characterized the resolution as permitting Mylan to launch generic dolutegravir before the full expiration of ViiV’s patent portfolio, subject to the negotiated license terms and applicable regulatory requirements.

The practical result was a delayed but defined generic-entry scenario:

• Mylan avoided an immediate launch risk.
• ViiV avoided the possibility of an adverse invalidity decision.
• The market received a future generic-entry date rather than an immediate competitive launch.
• Other generic applicants could create separate entry risks if they pursued different challenges or reached independent settlements.

A settlement with one ANDA applicant does not automatically prevent other ANDA filers from challenging the same patents. The effect depends on the applicant’s filing date, Paragraph IV status, first-filer rights, settlement terms, and FDA approval posture.

What is the Orange Book status of Tivicay?

FDA Orange Book listings for Tivicay identify patents associated with the product and provide the regulatory framework for ANDA certification. The relevant patents included compound and method-of-use rights associated with dolutegravir.

Orange Book issue	Analysis
Listed drug	Tivicay
Listed patent type	Drug substance and method-of-use protection
ANDA certification	Paragraph IV
Regulatory effect	Patent litigation and 30-month stay
Commercial consequence	Delayed generic approval or licensed entry
Biosimilar pathway	Not applicable

Patent expiration dates in the Orange Book can differ from the nominal 20-year patent term because of patent-term adjustment, patent-term extension, pediatric exclusivity, and FDA listing conventions. The operative commercial date must be determined from the current Orange Book entry, the patent record, and any applicable exclusivity period. (FDA, 2024; U.S. Patent and Trademark Office [USPTO], n.d.)

What formulation patents protect dolutegravir?

The ViiV-Mylan dispute was principally a compound and method-of-use case, not a case centered on a differentiated extended-release or specialty-delivery formulation.

Dolutegravir is administered as an immediate-release oral tablet. Generic applicants can generally pursue conventional tablet formulations without copying a branded manufacturing process, provided that the resulting product satisfies FDA bioequivalence requirements and does not infringe valid formulation or composition claims.

The principal barriers were therefore:

• The dolutegravir compound claims.
• Pharmaceutical composition claims covering the active ingredient.
• HIV-treatment method claims.
• Regulatory timing created by the Paragraph IV litigation.

ViiV’s broader product portfolio created additional patent considerations for fixed-dose combinations. Triumeq and Juluca contain dolutegravir with other antiretroviral agents and may have separate patents, regulatory exclusivities, and litigation histories. A generic dolutegravir tablet does not automatically establish a right to market a generic version of those combination products.

Did biosimilar risk affect this litigation?

No. Dolutegravir is a chemically synthesized small-molecule drug. The relevant competitive pathway was the Hatch-Waxman ANDA process, not the Biologics Price Competition and Innovation Act biosimilar pathway.

The correct competitive questions were:

• Whether Mylan could obtain ANDA approval.
• Whether its Paragraph IV certifications were successful.
• Whether ViiV’s patents remained enforceable.
• Whether the settlement granted Mylan a licensed entry date.
• Whether additional generic companies could enter through separate patent challenges.

Which companies were potential generic competitors?

The settlement with Mylan did not eliminate broader generic risk. Other pharmaceutical companies could pursue generic dolutegravir through their own ANDAs, subject to the same patent landscape and any separate settlements.

Potential competitors in the broader market included established generic manufacturers with HIV portfolios, such as Teva, Lupin, Cipla, and other ANDA sponsors. The effect of a competing filer depended on whether it was a first Paragraph IV filer, whether it had 180-day exclusivity, and whether its product targeted Tivicay alone or a combination product.

ViiV also faced product-substitution risk from its own portfolio. If physicians shifted between Tivicay, Triumeq, Juluca, and other integrase-inhibitor regimens, generic dolutegravir could affect more than the standalone Tivicay revenue stream.

What revenue exposure did the case create?

Tivicay was a high-value HIV product and an important component of ViiV’s dolutegravir franchise. Generic entry could affect revenue through:

• Direct price erosion for standalone dolutegravir tablets.
• Formulary substitution.
• Reduced prescribing of branded Tivicay.
• Pressure on combination-product pricing.
• Contracting concessions before actual generic launch.

The settlement reduced near-term launch uncertainty but did not remove long-term erosion risk. Once a licensed generic enters, HIV products may experience slower substitution than some acute-care medicines because treatment continuity, physician familiarity, and regimen management matter. Price competition nevertheless increases as additional ANDA products receive approval.

How does this case compare with a typical ANDA patent settlement?

ViiV v. Mylan followed the standard structure of an ANDA patent dispute:

1. Mylan filed an ANDA with Paragraph IV certifications.
2. ViiV filed suit within the statutory deadline.
3. FDA approval was subject to the Hatch-Waxman litigation stay.
4. The parties resolved the case without a reported trial judgment.
5. Mylan received a future licensed-entry opportunity.

The settlement’s commercial value rested on timing. ViiV preserved branded exclusivity before the agreed entry date, while Mylan received a predictable launch path and avoided the risk of losing its ANDA challenge after trial.

What generic launch risks remain?

The main launch risks are timing, patent scope, and competing entrants.

Timing risk

Mylan’s licensed entry date controls its ability to commercialize under the settlement. FDA approval alone would not authorize launch before the contractual or patent-based restrictions expire.

Patent risk

The compound patent is the main barrier because it covers the active ingredient itself. Method-of-use patents may be more vulnerable to labeling strategies, but their effect depends on the scope of the proposed label and the approved indications.

Competing-entry risk

A separate generic applicant may obtain approval through a different settlement, a successful invalidity decision, or expiration of the relevant patents. The first commercial generic could materially change the economics for later entrants.

Manufacturing and supply risk

Generic manufacturers must establish compliant production, analytical controls, stability data, and bioequivalence. Dolutegravir is not generally viewed as a biologic manufacturing barrier, but controlled HIV supply chains and regulatory inspection readiness remain operational requirements.

Key Takeaways

• ViiV sued Mylan in 2017 over an ANDA for generic dolutegravir tablets.
• The case involved U.S. Patent Nos. 8,129,385 and 8,754,065.
• The ’385 patent provided core compound protection for dolutegravir.
• The ’065 patent covered HIV-treatment methods involving dolutegravir.
• Mylan used Paragraph IV certifications to challenge ViiV’s patent rights.
• The case ended through settlement, not a reported Delaware trial judgment.
• The settlement created a future licensed-entry pathway for Mylan.
• Biosimilar law was not relevant because dolutegravir is a small-molecule drug.
• The primary commercial risk was generic erosion of Tivicay and related dolutegravir franchise revenue.
• Additional generic entry remained possible through separate ANDA challenges and settlements.

FAQs About ViiV Healthcare v. Mylan

What was the drug in ViiV Healthcare v. Mylan?

The case concerned generic dolutegravir tablets, the active ingredient in ViiV’s Tivicay product.

Was Mylan allowed to launch generic Tivicay immediately?

No. Mylan’s entry was subject to the settlement’s negotiated license terms and the applicable patent and FDA approval requirements.

Did ViiV win the case at trial?

No reported merits judgment decided the case. The litigation ended through settlement.

Did the case involve Triumeq or Juluca?

The dispute centered on standalone dolutegravir tablets. Triumeq and Juluca have separate combination-product and patent considerations.

Is dolutegravir subject to biosimilar competition?

No. Dolutegravir is a small-molecule drug, so competitors use the ANDA pathway rather than the biosimilar pathway.

References

Food and Drug Administration. (2013). FDA approves new HIV drug Tivicay. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

U.S. District Court for the District of Delaware. (2017). ViiV Healthcare Company v. Mylan Pharmaceuticals, Inc., No. 1:17-cv-00197.

U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 8,129,385 and 8,754,065. U.S. Department of Commerce.

United States Code. (2023). 21 U.S.C. § 355: New drugs. Congress.gov.